Elham Hassen

Summary

Country: France

Publications

  1. ncbi request reprint TAP1 gene polymorphisms and nasopharyngeal carcinoma risk in a Tunisian population
    Elham Hassen
    Laboratoire d Immuno Oncologie Moleculaire, Faculte de medecine de Monastir, 5019 Monastir, Tunisia
    Cancer Genet Cytogenet 175:41-6. 2007
  2. pmc Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma
    Achraf Khedhaier
    Laboratoire d Immuno Oncologie Moleculaire, Faculte de medecine de Monastir, Tunisia
    BMC Cancer 8:109. 2008
  3. pmc Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population
    Wijden Mahfoudh
    Department of Molecular Immuno Oncology, Faculty of Medicine, 5019 Monastir, Tunisia
    Mol Biol Rep 39:1037-46. 2012
  4. ncbi request reprint Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome
    Sana Sfar
    Laboratoire d Immuno Oncologie Moleculaire, Faculte de medecine de Monastir, Universite de Monastir, Tunisia
    Cytokine 35:21-8. 2006
  5. doi request reprint Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients
    Karim Farhat
    Laboratory of Molecular Immuno Oncology, Faculty of Medicine of Monastir, Monastir 5019, Tunisia
    Cytokine 43:132-7. 2008

Collaborators

Detail Information

Publications5

  1. ncbi request reprint TAP1 gene polymorphisms and nasopharyngeal carcinoma risk in a Tunisian population
    Elham Hassen
    Laboratoire d Immuno Oncologie Moleculaire, Faculte de medecine de Monastir, 5019 Monastir, Tunisia
    Cancer Genet Cytogenet 175:41-6. 2007
    ..These results back up the fact that the etiology of NPC in intermediate-risk countries is completely different in each peak of age prevalence and that each peak may possess its own particular oncogenic mechanism...
  2. pmc Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma
    Achraf Khedhaier
    Laboratoire d Immuno Oncologie Moleculaire, Faculte de medecine de Monastir, Tunisia
    BMC Cancer 8:109. 2008
    ..This study investigated the susceptibility and prognostic implications of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene polymorphisms in breast carcinoma patients...
  3. pmc Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population
    Wijden Mahfoudh
    Department of Molecular Immuno Oncology, Faculty of Medicine, 5019 Monastir, Tunisia
    Mol Biol Rep 39:1037-46. 2012
    ..This suggests that the c.798_799delTT mutation is a Tunisian founder mutation. Our findings indicate that the Tunisian population has a spectrum of prevalent BRCA1 mutations, some of which appear as recurrent and founding mutations...
  4. ncbi request reprint Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome
    Sana Sfar
    Laboratoire d Immuno Oncologie Moleculaire, Faculte de medecine de Monastir, Universite de Monastir, Tunisia
    Cytokine 35:21-8. 2006
    ..We evaluated the role of the functional VEGF polymorphisms as genetic markers for PCa susceptibility and prognosis...
  5. doi request reprint Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients
    Karim Farhat
    Laboratory of Molecular Immuno Oncology, Faculty of Medicine of Monastir, Monastir 5019, Tunisia
    Cytokine 43:132-7. 2008
    ..In this study we wanted to know whether IL-18 polymorphisms at positions -607 C/A and -137 G/A are associated with susceptibility and/or are markers of nasopharyngeal carcinoma (NPC) prognosis...